RESUMEN
BACKGROUND: Evidence suggests that selenium supplementation could be useful in the treatment of Hashimoto thyroiditis (HT), but the available trials are heterogeneous. This study investigates clinically relevant effects of selenium supplementation in patients with HT. METHODS: A systematic search was performed in PubMed, Web of Science, EMBASE, Scopus, and the Cochrane Library. The latest update was performed on December 3, 2022. We investigated the changes in thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb) after selenium supplementation. The effect sizes were expressed as weighted mean difference (WMD) with 95% confidence intervals (CIs). RESULTS: After screening and full-text assessment, 7 controlled trials comprising 342 patients were included in the systematic review. The results showed that there was no significant change in TPOAb levels (WMD = -124.28 [95% CI: -631.08 to 382.52], P = .631, I2 = 94.5%) after 3 months of treatment. But there was a significant decrease in TPOAb levels (WMD = -284.00 [95% CI: -553.41 to -14.60], P < .05, I2 = 93.9%) and TgAb levels (WMD = -159.86 [95% CI: -293.48 to -26.24], P < .05, I2 = 85.3%) after 6 months of treatment. CONCLUSIONS: Selenium supplementation reduces serum TPOAb and TgAb levels after 6 months of treatment in patients with HT, but future studies are warranted to evaluate health-related quality or disease progression.
Asunto(s)
Enfermedad de Hashimoto , Selenio , Humanos , Selenio/administración & dosificación , Selenio/uso terapéutico , Suplementos Dietéticos , Enfermedad de Hashimoto/tratamiento farmacológico , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/efectos de los fármacos , Tiroglobulina/sangre , Tiroglobulina/efectos de los fármacosRESUMEN
BACKGROUND: Prunella vulgaris (PV), a traditional Chinese medical herb, is considered beneficial for some thyroid diseases. However, the effectiveness is not consistent in different studies. This review compiles the evidence from randomized controlled trials (RCTs) and quantifies the effects of PV preparation on thyroid nodules. METHODS: Eight databases were searched up to April 2021 to identify eligible studies. Only RCTs were included. Meta-analysis of homogeneous studies was performed by RevMan5.3 software. Cochrane risk of bias assessment tool version 2.0 was used to assess the risk of bias of each trial. The research screening, data extraction, and risk of bias assessment were employed by 2 reviewers independently, and disagreement will be decided by a third senior reviewer. The risk ratio (RR), mean difference (MD) and corresponding 95% confidence interval (CI) of each study are summarized. RESULTS: Thirteen RCTs with 1468 patients were included in this study. A meta-analysis showed that the RR of the clinical efficacy of PV combined with levothyroxine sodium tablets was 1.22 (95% CI [1.11, 1.33]). The MD of thyroid nodule diameter was -0.43 (95% CI [-0.63, -0.22]). The MD of free triiodothyronine and free tetraiodothyronine levels was -1.99 (95% CI [-3.14, -0.86]) and -3.20 (95% CI [-5.50, -0.89]), respectively. The RR of the adverse reaction rate was 0.67 (95% CI [0.36, 1.22]), and the RR of the clinical efficacy of PV preparation combined with thyroxin tablets was 1.29 (95% CI [1.03, 1.62]). CONCLUSIONS: PV combined with levothyroxine sodium tablets or thyroxin tablets has more benefits for thyroid nodules, further improving the clinical efficiency, reducing the diameter of nodules and reducing the occurrence of adverse reactions. However, the quality of these studies is uncertain, and higher quality and more RCTs are needed to provide comprehensive evidence-based medical evidence in the future.
Asunto(s)
Lamiaceae/efectos adversos , Prunella/efectos adversos , Nódulo Tiroideo/tratamiento farmacológico , Estudios de Casos y Controles , Composición de Medicamentos/métodos , Quimioterapia Combinada , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Humanos , Yoduro Peroxidasa/sangre , Lamiaceae/química , Masculino , Medicina Tradicional China/métodos , Prunella/química , Ensayos Clínicos Controlados Aleatorios como Asunto , Seguridad , Nódulo Tiroideo/patología , Tiroxina/administración & dosificación , Tiroxina/uso terapéutico , Resultado del Tratamiento , Triyodotironina/sangreRESUMEN
INTRODUCTION: The objective of this study was to evaluate the effect of selenium supplementation on autoantibody titres, thyroid ultrasonography, and thyroid function in patients with Hashimoto's thyroiditis (autoimmune thyroiditis) and normal thyroid reference range. MATERIAL AND METHODS: A total of 100 patients were given 200 ug/d selenium yeast orally, their thyroid function, levels of serum selenium, thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TGAb), and urine iodine were measured, and thyroid ultrasonography was performed before administration and three and six months afterwards, and the data were statistically analysed. RESULTS: The subjects exhibited a selenium deficiency before the administration of selenium, and the serum levels increased to moderate levels three and six months after the selenium supplementation (p < 0.05). The titres of TGAb decreased significantly in patients after six months of selenium supplementation (p < 0.05). In the high antibody group, TgAb decreased after 6 months compared with baseline (p = p < 0.05), and TPOAb decreased after 3 and 6 months of selenium supplementation compared with baseline (p < 0.05). CONCLUSION: In patients with autoimmune thyroiditis and normal thyroid reference range, there was a general selenium deficiency, but after six months of treatment it was shown that selenium supplementation may be effective in reducing the titres of TGAb and TPOAb.
Asunto(s)
Anticuerpos/sangre , Autoanticuerpos/sangre , Enfermedad de Hashimoto/tratamiento farmacológico , Enfermedad de Hashimoto/inmunología , Yoduro Peroxidasa/sangre , Selenio/uso terapéutico , Tiroglobulina/sangre , Autoanticuerpos/análisis , Suplementos Dietéticos , Enfermedad de Hashimoto/sangre , Humanos , Yoduro Peroxidasa/inmunología , Selenio/sangre , Tiroglobulina/inmunología , Glándula Tiroides/fisiologíaRESUMEN
BACKGROUND: Iodine is an essential nutrient for human health throughout the life cycle, especially during early stages of intrauterine life and infancy, to ensure adequate neurocognitive development. The growing global reliance on desalinated iodine-diluted water raises the specter of increased iodine deficiency in several regions. The case of Israel may be instructive for exploring the link between iodine status and habitual iodine intake in the setting of extensive national reliance on desalinated water. The aim of this study was to explore the relationship between iodine intake, including iodized salt and iodine-containing supplements intake, and iodine status among pregnant women residing in a sub-district of Israel that is highly reliant on desalinated iodine-diluted water. METHODS: A total of 134 consecutive pregnant women were recruited on a voluntary basis from the obstetrics department of the Barzilai University Medical Center during 2018. Blood was drawn from participants to determine levels of serum thyrotropin (TSH), thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb) and thyroglobulin (Tg). An iodine food frequency questionnaire (sIFFQ) was used to assess iodine intake from food, IS and ICS. A questionnaire was used to collect data on demographic and health characteristics. RESULTS: A total of 105 pregnant women without known or reported thyroid disease were included in the study. Elevated Tg values (≥ 13 µg/L), were found among 67% of participants, indicating insufficient iodine status. The estimated iodine intake (median, mean ± SD 189, 187 ± 106 µg/d by sIFFQ) was lower than the levels recommended by the World Health Organization and the Institute of Medicine (250 vs. 220 µg/day respectively). The prevalence of iodized salt intake and iodine containing supplement intake were 4 and 52% (respectively). Values of Tg > 13 µg/L were inversely associated with compliance with World Health Organization and Institute of Medicine recommendations. CONCLUSIONS: While the Israeli Ministry of Health has recommended the intake of iodized salt and iodine containing supplements, this is apparently insufficient for achieving optimal iodine status among Israeli pregnant women. The evidence of highly prevalent probable iodine deficiency in a sample of pregnant women suggests an urgent need for a national policy of iodized salt regulation, as well as guidelines to promote iodine containing supplements and adherence to them by caregivers. In addition, studies similar to this one should be undertaken in additional countries reliant on desalinated iodine-diluted water to further assess the impact of desalinization on maternal iodine status.
Asunto(s)
Política de Salud , Yodo/deficiencia , Mujeres Embarazadas , Cloruro de Sodio Dietético/farmacología , Dieta Hiposódica/efectos adversos , Dieta Hiposódica/tendencias , Femenino , Humanos , Yoduro Peroxidasa/análisis , Yoduro Peroxidasa/sangre , Yodo/análisis , Yodo/farmacología , Yodo/uso terapéutico , Israel/epidemiología , Valor Nutritivo , Embarazo , Cloruro de Sodio Dietético/uso terapéutico , Encuestas y Cuestionarios , Tiroglobulina/análisis , Tiroglobulina/sangre , Tirotropina/análisis , Tirotropina/sangreRESUMEN
BACKGROUND: Thyroid gland is a probable goal tissue for radiation-related injury. Occupational exposure to ionizing radiation leads to thyroid dysfunction and exposure to high dose may lead to thyroid carcinoma. OBJECTIVE: Evaluation of the role of Thyroid peroxidase antibody as a predictor for thyroid dysfunction among nurses and technicians in the radiology department in Mansoura Specialized Medical hospital (MSMH). SUBJECTS AND METHODS: Subjects were Nurses and technicians who are working in (MSMH) with persistent daily duty in the last 3 years and fulfilling the inclusion and exclusion criteria. All subjects included in the study were recruited in one month and divided into two groups; Group 1: 50 subjects who were working in radiology, coronary angiography and ERCP unit, Radiation -exposed group. Group 2: 33 subjects who were working in In-patient departments and in out- patient clinics and not exposed to any type of radiation. Non fasting blood sample was taken from all enrolled subjects for measurement of TSH and Anti-TPO. RESULTS: TPO was positively and significantly correlated to age, TSH, duration of radiology/ y (r=0.388, 0.364, 0.342respectively) p value <0.05. Roc curve was done to detect the sensitivity and specificity of TSH in relation to TPO that revealed the cutoff value of TSH > 1.69 with Sensitivity and Specificity. PPV, NPV and accuracy at cutoff >1.69 were 70.6%, 51.5%, 42.8%, 77.3% and 58%. CONCLUSION: Working personnel with positive anti TPO and their TSH levels are more than 1.69 associated with symptoms of hypothyroidism, a trial of treatment is mandatory to relieve symptoms.
Asunto(s)
Autoantígenos/sangre , Personal de Salud , Hospitales Especializados , Yoduro Peroxidasa/sangre , Proteínas de Unión a Hierro/sangre , Exposición Profesional/efectos adversos , Traumatismos por Radiación/sangre , Enfermedades de la Tiroides/sangre , Adulto , Autoanticuerpos/sangre , Autoanticuerpos/efectos de la radiación , Autoantígenos/efectos de la radiación , Estudios Transversales , Egipto/epidemiología , Femenino , Humanos , Yoduro Peroxidasa/efectos de la radiación , Proteínas de Unión a Hierro/efectos de la radiación , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Exposición a la Radiación/efectos adversos , Traumatismos por Radiación/diagnóstico , Enfermedades de la Tiroides/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Both exogenous vitamin D and selenium reduce thyroid antibody titers. The aim of the study was to investigate whether the impact of vitamin D on thyroid autoimmunity is affected by selenium intake. METHODS: The study included 47 euthyroid women with Hashimoto's thyroiditis and low vitamin D status, 23 of whom had been treated with selenomethionine (200 µg daily) for at least 12 months before the beginning of the study. During the study, all patients were treated with vitamin D preparations (4000 IU daily). Serum titers of thyroid peroxidase and thyroglobulin antibodies, as well as circulating levels of thyrotropin, free thyroid hormones and 25-hydroxyvitamin D were measured before vitamin D supplementation and 6 months later. Moreover, at the beginning and at the end of the study, we calculated Jostel's thyrotropin index, the SPINA-GT index and the SPINA-GD index. RESULTS: With the exception of the free triiodothyronine/free thyroxine ratio and the SPINA-GD index, there were no differences between the study groups. In both groups, vitamin D increased 25-hydroxyvitamin D levels, reduced thyroid peroxidase and thyroglobulin antibody titers, as well as increased the SPINA-GT index. The effects on antibody titers and the SPINA-GT index were more pronounced in women receiving selenomethionine. Neither in selenomethionine-treated nor in selenomethionine-naïve women vitamin D affected serum hormone levels, Jostel's index and the SPINA-GD index. CONCLUSIONS: The results of the study suggest that selenium intake enhances the effect of vitamin D on thyroid autoimmunity.
Asunto(s)
Autoinmunidad/efectos de los fármacos , Enfermedad de Hashimoto/tratamiento farmacológico , Selenometionina/farmacología , Vitamina D/administración & dosificación , Adulto , Autoanticuerpos/sangre , Autoantígenos/sangre , Autoinmunidad/inmunología , Femenino , Enfermedad de Hashimoto/sangre , Enfermedad de Hashimoto/inmunología , Humanos , Yoduro Peroxidasa/sangre , Proteínas de Unión a Hierro/sangre , Persona de Mediana Edad , Tiroglobulina/sangre , Hormonas Tiroideas/sangre , Vitamina D/análogos & derivados , Vitamina D/sangre , Adulto JovenRESUMEN
BACKGROUND: Both selenium and vitamin D were found to reduce thyroid antibody titers in women with Hashimoto's thyroiditis. METHODS: The study enrolled 37 young drug-naïve euthyroid men with autoimmune thyroiditis, who were treated for 6 months with either exogenous vitamin D (group A, n = 20) or selenomethionine (group B, n = 17). Serum titers of thyroid peroxidase and thyroglobulin antibodies, serum levels of thyrotropin and free thyroid hormones, serum levels of 25-hydroxyvitamin D, as well Jostel's thyrotropin, the SPINA-GT and the SPINA-GD indices were determined at the beginning and at the end of the study. RESULTS: At baseline, there were no differences between the study groups. Both vitamin D and selenomethionine reduced antibody titers and increased the SPINA-GT index. Only selenomethionine affected the SPINA-GD index, while only vitamin D increased 25-hydroxyvitamin D levels. Neither selenomethionine nor vitamin D significantly affected thyrotropin and free thyroid hormone levels. The effect of vitamin D on antibody titers correlated with baseline and treatment-induced changes in serum levels of 25-hydroxivitamin D. CONCLUSIONS: Both vitamin D and selenomethionine have a beneficial effect on thyroid autoimmunity in drug-naïve men with Hashimoto's thyroiditis.
Asunto(s)
Enfermedad de Hashimoto/sangre , Selenometionina/administración & dosificación , Hormonas Tiroideas/sangre , Vitamina D/administración & dosificación , Adulto , Autoanticuerpos/sangre , Autoantígenos/sangre , Autoinmunidad/inmunología , Suplementos Dietéticos , Enfermedad de Hashimoto/inmunología , Humanos , Sistema Hipotálamo-Hipofisario/metabolismo , Yoduro Peroxidasa/sangre , Proteínas de Unión a Hierro/sangre , Masculino , Proyectos Piloto , Hipófisis/metabolismo , Selenometionina/farmacología , Pruebas de Función de la Tiroides , Tirotropina/sangre , Vitamina D/análogos & derivados , Vitamina D/sangreRESUMEN
OBJECTIVES: American Thyroid Association (ATA)'s new guidelines recommend use of population-based trimester-specific reference range (RR) for thyrotropin (TSH) in pregnancy. The aim of this study was to determine first trimester TSH RR for a population of pregnant women in Rio de Janeiro State. SUBJECTS AND METHODS: Two hundred and seventy pregnant women without thyroid illness, defined by National Academy of Clinical Biochemistry, and normal iodine status were included in this sectional study. This reference group (RG) had normal median urinary iodine concentration (UIC = 219 µg/L) and negative anti-thyroperoxidase antibodies (TPOAb). Twin pregnancy, trophoblastic disease and use of drugs or supplements that influence thyroid function were excluded. In a second step, we defined a more selective reference group (SRG, n = 170) by excluding patients with thyroiditis pattern on thyroid ultrasound and positive anti-thyroglobulin antibodies. This group also had normal median UIC. At a final step, a more selective reference group (MSRG, n = 130) was defined by excluding any pregnant women with UIC < 150 µg/L. RESULTS: In the RG, median, 2.5th and 97.5th percentiles of TSH were 1.3, 0.1, and 4.4 mIU/L, respectively. The mean age was 270 ± 5.0 and the mean body mass index was 25.6 ± 5.2 kg/m2. In the SRG and MSRG, 2.5th and 975th percentiles were 0.06 and 4.0 (SRG) and 0.1 and 3.6 mIU/L (MSRG), respectively. CONCLUSIONS: In the population studied,TSH upper limit in the first trimester of pregnancy was above 2.5 mIU/L. The value of 3.6 mIU/L, found when iodine deficiency and thyroiditis (defined by antibodies and ultrasound characteristics) were excluded, matches recent ATA guidelines.
Asunto(s)
Guías de Práctica Clínica como Asunto/normas , Primer Trimestre del Embarazo/sangre , Glándula Tiroides/diagnóstico por imagen , Tirotropina/sangre , Adulto , Autoanticuerpos/sangre , Autoantígenos/sangre , Brasil , Estudios Transversales , Femenino , Humanos , Yoduro Peroxidasa/sangre , Yodo/orina , Proteínas de Unión a Hierro/sangre , Embarazo , Valores de Referencia , Pruebas de Función de la Tiroides/normas , Tirotropina/normas , Ultrasonografía , Adulto JovenRESUMEN
ABSTRACT Objectives: American Thyroid Association (ATA)'s new guidelines recommend use of population-based trimester-specific reference range (RR) for thyrotropin (TSH) in pregnancy. The aim of this study was to determine first trimester TSH RR for a population of pregnant women in Rio de Janeiro State. Subjects and methods: Two hundred and seventy pregnant women without thyroid illness, defined by National Academy of Clinical Biochemistry, and normal iodine status were included in this sectional study. This reference group (RG) had normal median urinary iodine concentration (UIC = 219 μg/L) and negative anti-thyroperoxidase antibodies (TPOAb). Twin pregnancy, trophoblastic disease and use of drugs or supplements that influence thyroid function were excluded. In a second step, we defined a more selective reference group (SRG, n = 170) by excluding patients with thyroiditis pattern on thyroid ultrasound and positive anti-thyroglobulin antibodies. This group also had normal median UIC. At a final step, a more selective reference group (MSRG, n = 130) was defined by excluding any pregnant women with UIC < 150 μg/L. Results: In the RG, median, 2.5th and 97.5th percentiles of TSH were 1.3, 0.1, and 4.4 mIU/L, respectively. The mean age was 270 ± 5.0 and the mean body mass index was 25.6 ± 5.2 kg/m2. In the SRG and MSRG, 2.5th and 975th percentiles were 0.06 and 4.0 (SRG) and 0.1 and 3.6 mIU/L (MSRG), respectively. Conclusions: In the population studied,TSH upper limit in the first trimester of pregnancy was above 2.5 mIU/L. The value of 3.6 mIU/L, found when iodine deficiency and thyroiditis (defined by antibodies and ultrasound characteristics) were excluded, matches recent ATA guidelines.
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Adulto Joven , Primer Trimestre del Embarazo/sangre , Glándula Tiroides/diagnóstico por imagen , Tirotropina/sangre , Guías de Práctica Clínica como Asunto/normas , Valores de Referencia , Autoanticuerpos/sangre , Autoantígenos/sangre , Pruebas de Función de la Tiroides/normas , Brasil , Tirotropina/normas , Estudios Transversales , Ultrasonografía , Proteínas de Unión a Hierro/sangre , Yoduro Peroxidasa/orina , Yoduro Peroxidasa/sangreRESUMEN
OBJECTIVE: Hashimoto encephalopathy is an autoimmune encephalopathy characterized by elevated antithyroid antibodies and a favorable response to corticosteroid. This study delineated the clinical characteristics of pediatric Hashimoto encephalopathy and the significance of low antithyroid antibody titers in diagnosis and treatment. SUBJECTS AND METHODS: Clinical manifestations, antibody titers, and treatment responses were retrospectively reviewed in six consecutive children diagnosed with Hashimoto encephalopathy between August 2008 and July 2016. RESULTS: Age at diagnosis was 10-17years. Presenting symptoms were seizures, altered consciousness, behavioral changes, psychosis, tremor, and dystonia. Thyroid function was normal in five patients, and one had hypothyroidism prior to the encephalopathy. Antithyroid antibody titer was increased at presentation in five patients and one week later in the other. Antibody levels were extremely varied (anti-thyroglobulin, 20.5-2318.0U/ml; anti-thyroid peroxidase, 12.5-2231.0U/ml; reference range, <60U/ml) and <180U/ml in two patients. Electroencephalogram was abnormal in five patients. Brain magnetic resonance imaging was unremarkable. Four patients responded to high-dose corticosteroid and one improved with additional intravenous immunoglobulin. The remaining patient did not respond to both treatments and normalized after plasmapheresis. Autoantibody titers decreased with treatment response in the acute stage. Two patients with low antibody titers showed similar clinical presentations and responses. CONCLUSIONS: The clinical presentations and treatment responses in Hashimoto encephalopathy were similar, irrespective of antithyroid antibody titer. Because the initial antithyroid antibody titers can be normal or mildly-elevated, follow-up testing of antithyroid antibodies is required in patients who are clinically suspect for Hashimoto encephalopathy.
Asunto(s)
Encefalitis/inmunología , Encefalitis/fisiopatología , Enfermedad de Hashimoto/inmunología , Enfermedad de Hashimoto/fisiopatología , Adolescente , Corticoesteroides/uso terapéutico , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Encéfalo/patología , Encefalopatías/diagnóstico , Encefalopatías/tratamiento farmacológico , Niño , Electroencefalografía/métodos , Encefalitis/diagnóstico , Femenino , Enfermedad de Hashimoto/diagnóstico , Humanos , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/inmunología , Proteínas de Unión a Hierro/inmunología , Masculino , Estudios Retrospectivos , Convulsiones/tratamiento farmacológicoRESUMEN
UNLABELLED: A new method of reduction of autoimmune process activity related to the thyroid in patients without signs of thyroiditis is presented in the article (patent of Ukraine No. 103742). New patents and inventions from different countries of the world related to the problem have been analysed. MATERIALS AND METHODS: Sixty one patients with a significant disturbance of tolerance to the thyroid antigens in the absence of disturbance of the thyroid function were involved in the research. Twenty two patients with chronic hepatitis C, genotype 1 HCV, receiving antiviral therapy, were also included in the research. Patients were immunized intracutaneously with autoleukocytes for autoimmune process inhibition. After single immunization with autoleukocytes decrease in the level of antibodies against the thyroid antigens was observed in all patients. In some patients without chronic hepatitis C the levels of thyroperoxidase and thyroglobulin antibodies decreased by 50% and more (33.33% and 20.51%, respectively). In patients with ChHC these indices were considerably lower, and the duration of the achieved effect was shorter. However, immunization inhibited activity of immune process in patients with ChHC due to interferon therapy. The suggested method enables to decrease the threat for thyroiditis development even in patients with chronic hepatitis C during antiviral therapy.
Asunto(s)
Autoanticuerpos/biosíntesis , Autoanticuerpos/inmunología , Patentes como Asunto , Glándula Tiroides/inmunología , Glándula Tiroides/fisiología , Antivirales/uso terapéutico , Autoinmunidad/inmunología , Transfusión de Sangre Autóloga , Femenino , Hepatitis C Crónica/sangre , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/inmunología , Humanos , Inmunización , Yoduro Peroxidasa/sangre , Leucocitos/inmunología , Masculino , Tiroglobulina/sangre , UcraniaRESUMEN
The purpose of modelling the negative-feedback control mechanism of the hypothalamus-pituitary-thyroid (HPT) axis in autoimmune (Hashimoto's) thyroiditis is to describe the clinical course of euthyroidism, subclinical hypothyroidism and overt hypothyroidism for patients. Thyroid hormone thyroxine (T4) and triiodothyronine (T3) levels are controlled by negative-feedback control through thyroid-stimulating hormone (TSH). T4, like other hormones, can be bound or unbound; the unbound T4 (FT4) is used as a marker for hypothyroidism. Autoimmune thyroiditis is a disease in which the thyroid-infiltrating lymphocytes attack autoantigens in follicle cells, destroying them over a long time. To describe the operation of the feedback control, we developed a mathematical model involving four clinical variables: TSH, FT4, anti-thyroid peroxidase antibodies and the thyroid gland's functional size. The first three variables are regularly measured while the last variable is determined through relationships between the other three variables. The problem of two different time scales for circulating hormones and thyroid damage is addressed using singular perturbation theory. Analysis of the mathematical model establishes stability and conditions under which the diseased state can maintain the slow movement toward diseased state equilibrium. Although we have used four variables in modelling the feedback control through the HPT axis, the predicted clinical course given any set of parameters is shown to depend on the steady-state levels of TSH and FT4. This observation makes possible the development of the clinical charts based only on the levels of TSH, time and potential steady-state values. To validate the model predictions, a dataset obtained from a Sicilian adult population has been employed.
Asunto(s)
Enfermedad de Hashimoto/inmunología , Hipotálamo/inmunología , Modelos Inmunológicos , Hipófisis/inmunología , Glándula Tiroides/inmunología , Simulación por Computador , Retroalimentación , Enfermedad de Hashimoto/sangre , Humanos , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/inmunología , Sicilia , Tirotropina/sangre , Tirotropina/inmunología , Tiroxina/sangre , Tiroxina/inmunología , Triyodotironina/inmunologíaRESUMEN
Livestock are frequently provided nutrient-depleted diets, which can negatively impact animal health and productivity. In our previous trial, we found that iodine (I) supplementation (not selenium (Se)) could increase cashmere production. In order to explore the role of I and Se in cashmere growth, we investigated the effects of dietary I and Se supplementation in Liaoning cashmere goats. Serum thyroid hormone status and the mRNA expression levels of skin monodeiodinase (MDII, MDIII) were measured during the cashmere fiber growth period. Forty-eight 2.5-year-old Liaoning cashmere goats (38.6 ± 2.65 kg BW) were divided into six equal groups, and their diets were supplemented with I (0, 2, or 4 mg/kg DM) and Se (0 or 1 mg/kg DM) in a 2 × 3 factorial treatment design. The six treatment groups were: I(0)Se(0), I(2)Se(0), I(4)Se(0), I(0)Se(1), I(2)Se(1), and I(4)Se(1). Concentrations of I and Se in the basal diet (group I(0)Se(0)) were 0.67 and 0.09 mg/kg DM, respectively. The trial started in September of 2009 and lasted 70 days. For every measured parameter, supplemental Se had no significant effect on thyroid hormones, but improved the mRNA expression levels of skin MDIII (P < 0.01). However, supplemental I increased levels of thyroid hormones (thyroxine and triiodothyronine) and improved the mRNA expression levels of skin MDII (P < 0.05). These results show that the addition of I to cashmere goat feedstock may be an effective means of increasing cashmere production through thyroid hormones regulating the mRNA expression of skin MDII.
Asunto(s)
Suplementos Dietéticos , Cabras/genética , Yoduro Peroxidasa/genética , Yodo/farmacología , ARN Mensajero/efectos de los fármacos , Selenio/farmacología , Piel/enzimología , Animales , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/metabolismo , Yodo/administración & dosificación , Yodo/sangre , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Selenio/administración & dosificación , Selenio/sangre , Piel/metabolismo , Yodotironina Deyodinasa Tipo IIRESUMEN
Catechins, the flavonoids found in abundance in green tea, have many beneficial health effects such as antioxidative, anticarcinogenic, anti-inflammatory, antiallergic, and hypotensive properties. However, flavonoids have antithyroid/goitrogenic effect, although less information is available about the effect of pure catechin on thyroid physiology. The present investigation has been undertaken to explore the effect of catechin administration on thyroid physiology in rat model. For the in vivo experiment catechin was injected intraperitoneally (i.p.) at doses of 10, 20 and 30 mg/kg body to male albino rats for 15 and 30 days, respectively, and thyroid activities were evaluated with respect to determination of serum levels of thyroid hormones, thyroid peroxidase, 5'-deiodinase I (5'-DI), and Na(+), K(+)-ATPase activities that are involved in the synthesis of thyroid hormone. Catechin decreased the activities of thyroid peroxidase and thyroidal 5'-deiodinase I, while Na(+), K(+)-ATPase activity significantly increased in dose-dependent manner; substantial decrease in serum T3 and T4 levels coupled with significant elevation of serum TSH were also noted. Histological examinations of the thyroid gland revealed marked hypertrophy and/or hyperplasia of the thyroid follicles with depleted colloid content. In in vitro study, short-term exposure of rat thyroid tissue to catechin at the concentrations of 0.10, 0.20, and 0.30 mg/ml leads to decrease in the activities of thyroid peroxidase and 5'-deiodinase I, while the activity of thyroidal Na(+), K(+)-ATPase remains unaltered even at high concentration of catechin treatment. The present study reinforces the concept that catechin, tea flavonoids possess potent antithyroid activity as evidenced from in vivo and in vitro studies.
Asunto(s)
Catequina/farmacología , Hipotiroidismo/inducido químicamente , Glándula Tiroides , Hormonas Tiroideas/metabolismo , Animales , Catequina/efectos adversos , Catequina/metabolismo , Hiperplasia/inducido químicamente , Hipertrofia/inducido químicamente , Yoduro Peroxidasa/sangre , Masculino , Ratas , Ratas Sprague-Dawley , ATPasa Intercambiadora de Sodio-Potasio/sangre , Té/metabolismo , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/enzimología , Glándula Tiroides/metabolismo , Hormonas Tiroideas/biosíntesis , Hormonas Tiroideas/sangre , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangreRESUMEN
BACKGROUND AND OBJECTIVES: Chronic autoimmune thyroiditis (CAT) remains the most common cause of acquired hypothyroidism. There is currently no therapy that is capable of regenerating CAT-damaged thyroid tissue. The objective of this study was to gauge the value of applying low-level laser therapy (LLLT) in CAT patients based on both ultrasound studies (USs) and evaluations of thyroid function and thyroid autoantibodies. STUDY DESIGN/MATERIALS AND METHODS: Fifteen patients who had hypothyroidism caused by CAT and were undergoing levothyroxine (LT4) treatment were selected to participate in the study. Patients received 10 applications of LLLT (830 nm, output power 50 mW) in continuous mode, twice a week, using either the punctual technique (8 patients) or the sweep technique (7 patients), with fluence in the range of 38-108 J/cm(2). USs were performed prior to and 30 days after LLLT. USs included a quantitative analysis of echogenicity through a gray-scale computerized histogram index (EI). Following the second ultrasound (30 days after LLLT), LT4 was discontinued in all patients and, if required, reintroduced. Triiodothyronine, thyroxine (T4), free T4, thyrotropin, thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) antibodies levels were assessed before LLLT and then 1, 2, 3, 6, and 9 months after LT4 withdrawal. RESULTS: We noted all patients' reduced LT4 dosage needs, including 7 (47%) who did not require any LT4 through the 9-month follow-up. The LT4 dosage used pre-LLLT (96 +/- 22 microg/day) decreased in the 9th month of follow-up (38 +/- 23 microg/day; P < 0.0001). TPOAb levels also decreased (pre-LLLT = 982 +/- 530 U/ml, post-LLLT = 579 +/- 454 U/ml; P = 0.016). TgAb levels were not reduced, though we did observe a post-LLLT increase in the EI (pre-LLLT = 0.99 +/- 0.09, post-LLLT = 1.21 +/- 0.19; P = 0.001). CONCLUSION: The preliminary results indicate that LLLT promotes the improvement of thyroid function, as patients experienced a decreased need for LT4, a reduction in TPOAb levels, and an increase in parenchymal echogenicity.
Asunto(s)
Hipotiroidismo/terapia , Terapia por Luz de Baja Intensidad/métodos , Tiroiditis Autoinmune/terapia , Adulto , Autoanticuerpos/sangre , Enfermedad Crónica , Femenino , Humanos , Hipotiroidismo/sangre , Hipotiroidismo/etiología , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/inmunología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Tiroglobulina/sangre , Tiroglobulina/inmunología , Glándula Tiroides/diagnóstico por imagen , Tiroiditis Autoinmune/complicaciones , Tiroxina/sangre , Tiroxina/inmunología , Tiroxina/uso terapéutico , Triyodotironina/sangre , Triyodotironina/inmunología , UltrasonografíaRESUMEN
Catechins are flavonoids found in abundance in green tea, have elicited high interest due to their beneficial effects on health. Though flavonoids have been reported to have an antithyroid effect and also to be goitrogenic there have been no reports about the effect of green tea on rat thyroid. The present study was designed to examine whether high doses of green tea has any harmful effect on thyroid physiology. For this purpose green tea extract was administered orally to male albino rats for 30 days at doses of 1.25 g%, 2.5 g% and 5.0 g%, respectively. Similarly, pure catechin was administered at doses of 25, 50 and 100mg/kg body weight which is equivalent to above doses of green tea extract. Lower body weight gain associated with marked hypertrophy and/or hyperplasia of the follicles was noted in the high dose of green tea and catechin treated groups. Decreased activity of thyroid peroxidase and 5'-deiodinase I and substantially elevated thyroidal Na,K+ATPase activity have been observed. Moreover, serum T3 and T4 levels were found to reduce followed by significant elevation of serum TSH. Taken together, these results suggest that catechin present in green tea extract might behave as antithyroid agent and possibly the consumption of green tea at high dose could alter thyroid function adversely.
Asunto(s)
Antitiroideos/farmacología , Antitiroideos/toxicidad , Catequina/farmacología , Catequina/toxicidad , Bocio/inducido químicamente , Té/química , Animales , Antitiroideos/química , Peso Corporal/efectos de los fármacos , Catequina/química , Ensayo de Inmunoadsorción Enzimática , Yoduro Peroxidasa/sangre , Yoduro Peroxidasa/metabolismo , Tamaño de los Órganos/efectos de los fármacos , Extractos Vegetales/química , Extractos Vegetales/farmacología , Extractos Vegetales/toxicidad , Ratas , Ratas Sprague-Dawley , ATPasa Intercambiadora de Sodio-Potasio/sangre , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Glándula Tiroides/enzimología , Glándula Tiroides/patología , Hormonas Tiroideas/sangre , Tiroxina/sangre , Triyodotironina/sangreRESUMEN
OBJECTIVE: To longitudinally evaluate the timing of maternal thyroid underfunction occurrence in mildly iodine-deficient (ID) pregnant women, and ultimately assess the benefit of thyroid function testing at early gestation only in identifying maternal thyroid underfunction. PARTICIPANTS/METHODS: Serum free-thyroxine and TSH were measured in 220 consecutive women once in early pregnancy (by week 12) and twice per trimester subsequently. Anti-thyroperoxidase and anti-thyroglobulin were also determined at initial and final observation. RESULTS: Thyroid autoantibodies were detectable in 8.2% women. Overall, the prevalence of hypothyroidism over the course of gestation was 11.8% (26/220), with a relative risk of hypothyroidism in antibody-positive women of 5.0 (chi(2) 20.02, P<0.0005). Nonetheless, almost 70% hypothyroid women tested negative for thyroid autoantibodies. Fifteen/26 (57.7%) hypothyroid women were identified at presentation, and the remaining 11 at either early (6/11) or late (5/11) phases of the 2nd trimester. Isolated hypothyroxinemia was observed in 56/220 (25.4%) women, mostly from the 2nd trimester onwards. CONCLUSIONS: In mildly ID areas thyroid function testing early in gestation seems to be only partly effective in identifying thyroid underfunction in pregnant women. Indeed, in our series more than 40% hypothyroid women would not have been diagnosed had we limited our observation to early thyroid function tests alone. Although thyroid autoimmunity carried a 5-fold increased risk of hypothyroidism, iodine deficiency seems to be a major determinant in the occurrence of thyroid underfunction. Adequate iodine supplementation should be strongly recommended to meet the increased hormone demand over gestation.
Asunto(s)
Yodo/deficiencia , Complicaciones del Embarazo/diagnóstico , Enfermedades de la Tiroides/diagnóstico , Pruebas de Función de la Tiroides , Adulto , Femenino , Humanos , Hipotiroidismo/diagnóstico , Recién Nacido , Yoduro Peroxidasa/sangre , Italia , Estudios Longitudinales , Monitoreo Fisiológico , Embarazo , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/epidemiología , Resultado del Embarazo , Riesgo , Enfermedades de la Tiroides/sangre , Enfermedades de la Tiroides/epidemiología , Tirotropina/sangre , Tiroxina/sangre , Adulto JovenRESUMEN
Graves' disease, the most common cause of hyperthyroidism, is an autoimmune disorder. Antithyroid drugs have been selected as the first-line treatment of Graves' disease in Korea, Japan, and European countries. However, antithyroid drugs such as methimazole (MMI) and prophylthiouracil (PTU) have limitations in clinical applications because of their side effects. In this study, we performed a clinical trial and in vitro study to investigate the clinical effects and action mechanism of Ahnjeonbaekho-tang (AJBHT), an herbal remedy for Graves' disease. In a clinical study of Graves' disease patients who had side effects from antithyroid drugs, we found that treatment by AJBHT resulted in a reduction of serum triiodothyronine (T3) and free thyroxine (FT4) levels and an increase in thyroid stimulating hormone (TSH) levels (T3: p<0.0001, FT4: p=0.0012, TSH: p=0.0370, respectively). In vitro, AJBHT significantly inhibits FRTL-5 cell proliferation, DNA synthesis, cyclic AMP production, T4 synthesis, and the expression of thyroglobulin (Tg) mRNA in comparison with the control. These results suggest that AJBHT might suppress T(4) synthesis by modulating adenosine 3',5'-cyclic monophosphate (cAMP) and Tg expression, and therefore, AJBHT could be an alternative therapy for Graves' disease patients who have side effects from antithyroid drugs.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Medicamentos Herbarios Chinos/uso terapéutico , Enfermedad de Graves/tratamiento farmacológico , Fitoterapia , Animales , Línea Celular , Proliferación Celular/efectos de los fármacos , AMP Cíclico/biosíntesis , ADN/biosíntesis , Enfermedad de Graves/metabolismo , Humanos , Yoduro Peroxidasa/biosíntesis , Yoduro Peroxidasa/sangre , Extractos Vegetales/farmacología , ARN/biosíntesis , ARN/genética , Ratas , Ratas Endogámicas F344 , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sales de Tetrazolio , Tiazoles , Tiroglobulina/biosíntesis , Tiroglobulina/sangre , Tirotropina/biosíntesis , Tirotropina/sangre , Tiroxina/biosíntesis , Tiroxina/sangreRESUMEN
Hyperthyroidism in men is often treated with high doses of iodine-131 ((131)I), which may induce radiation side effects to patients and their environment. These therapeutic doses of (131)I could be decreased, if the (131)I uptake of the thyroid gland of the patients could be increased. Zinc sulphate has been considered to exercise a protective role by maintaining the cellular integrity of the thyroid under various pathological states. The aim of our study was to study in Wistar rats whether zinc sulphate can after treatment of the thyroid gland with (131)I: a) increase the uptake of (131)I in the thyroid and b) stabilize the function of the follicular cells. If such a stabilization finally exists in men we could have favorable results like fewer cases of hypothyroidism after (131)I treatment of hyperthyroidism. To carry out these investigations, rats were divided into four groups comprising of eight animals each. Group I animals served as normal controls. Group II animals received a dose of 3.7 MBq of (131)I. Group III animals were supplemented with zinc (227 mg/L of drinking water) and animals in Group IV were given (131)I together with zinc sulphate as above. Our results showed that in Group II, serum levels of tetra-iodo-thyronine (T(4)) and tri-iodo-thyronine (T(3)) decreased significantly as a function of time following (131)I treatment. An increase in the levels of serum thyroid stimulating hormone (TSH) was noticed one week after (131)I treatment, becoming less pronounced with time. In Group II, thyroid uptake at 2h and at 24h was significantly decreased. In the same Group biological half life (T(biol)) of (131)I in the thyroid gland, was significantly elevated four weeks after the administration of (131)I and decreased eight weeks after. In Group IV animals, zinc sulfate after four weeks, induced normalization of elevated serum TSH levels and a further increase in the T(biol) of (131)I. After eight weeks in these animals, serum T(3) became normal and TSH remained at normal levels. Thyroid (131)I uptake at 2 and 24 h was increased as compared to Group II. Group III animals showed some increase in the levels of Na(+)K(+)ATPase and type 1,5'-deiodinase (5'-DI) as compared to normal rats of Group I. In conclusion, this study suggests the protective potential of zinc sulphate in the disturbed after (131)I treatment, thyroid function, thyroid hormones and TSH while the (131)I uptake was reduced. Thus, if this result is further confirmed, zinc sulphate may show to be a promising radioprotective agent for the thyroid gland.
Asunto(s)
Radioisótopos de Yodo/administración & dosificación , Folículo Ovárico/efectos de los fármacos , Glándula Tiroides/efectos de los fármacos , Animales , Femenino , Hipotiroidismo/tratamiento farmacológico , Hipotiroidismo/metabolismo , Hipotiroidismo/patología , Yoduro Peroxidasa/sangre , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Cinética , Folículo Ovárico/citología , Folículo Ovárico/metabolismo , Ratas , Ratas Wistar , ATPasa Intercambiadora de Sodio-Potasio/sangre , Pruebas de Función de la Tiroides , Glándula Tiroides/metabolismo , Glándula Tiroides/patología , Tiroxina/sangre , Triyodotironina/sangre , Sulfato de Zinc/farmacocinética , Sulfato de Zinc/uso terapéuticoRESUMEN
OBJECTIVE: We studied the effects of selenium (Se) treatment on serum anti-thyroid peroxidase (TPO) levels in Greek patients with Hashimoto's thyroiditis (HT). DESIGN: We prospectively studied 80 women with HT, median age 37 (range 24-52) years, for 1 year. All patients received 200 microg Se in the form of l-selenomethionine orally for 6 months. At the end of the 6-month period, 40 patients continued taking 200 microg Se (Group A) and 40 patients stopped (Group B). Serum thyrotropin (TSH), free triiodothyronine (FT(3)), free thyroxine (FT(4)), anti-TPO, and anti-thyroglobulin (Tg) levels were measured at baseline and at the end of each 3-month period. MAIN OUTCOME: There was a significant reduction of serum anti-TPO levels during the first 6 months (by 5.6% and 9.9% at 3 and 6 months, respectively). An overall reduction of 21% (p < 0.0001) compared with the basal values was noted in Group A. In Group B, serum anti-TPO levels were increased by 4.8% (p < 0.0001) during the second 6-month period. CONCLUSIONS: Our study showed that in HT patients 6 months of Se treatment caused a significant decrease in serum anti-TPO levels, which was more profound in the second trimester. The extension of Se supplementation for 6 more months resulted in an additional 8% decrease, while the cessation caused a 4.8% increase, in the anti-TPO concentrations.